In their initial report of an ongoing investigation into the role of Sprouty in ovarian cancer, Masoumi-Moghaddam et al. later documented differential expression of Spry1 and Spry2 in a panel of ovarian cancer cells where a tendency for downregulation of Spry1 and/or Spry2 was evident [175]. This evidence concerns the gene SPRY2 and ovarian cancer.